growth factor combinations with G-CSF might enhance these differences. Keywords: G-CSF; GM-CSF; stem cell mobilization Fifty patients with either lymphoid or selected solid tumor malignancies were apheresed an identical number of times for PBSC collection after being randomized to receive either G-CSF 10 g/kg/day alone (arm I), or PBSC collected using several different strategies to G-CSF at the same dose with GM-CSF 5 g/kg/day enhance the number of circulating progenitor and CD34 + (arm II). Growth factor(s) was/were given as the stem cells results in equally rapid neutrophil recovery after cell mobilizing agent for 5 days before the start of PBSC HDCT as autologous bone marrow transplant (ABMT) collection, and were continued throughout the 4 days of given in combination with recombinant myeloid growth apheresis. Aspiration and cryopreservation of autologfactors (GF). [1] [2][3][4] However, platelet recovery is particularly ous bone marrow occurred on day 3 or 4 of growth enhanced after PBSC infusion compared with ABMT.
(arm II). Growth factor(s) was/were given as the stem cells results in equally rapid neutrophil recovery after cell mobilizing agent for 5 days before the start of PBSC HDCT as autologous bone marrow transplant (ABMT) collection, and were continued throughout the 4 days of given in combination with recombinant myeloid growth apheresis. Aspiration and cryopreservation of autologfactors (GF). [1] [2] [3] [4] However, platelet recovery is particularly ous bone marrow occurred on day 3 or 4 of growth enhanced after PBSC infusion compared with ABMT.
4-17 factor(s). Thirty-one of 50 patients received one cycle
Although PBSC may be collected in the steady-state, only at time of evaluation, and 19 patients received two mobilization techniques increase the pool of circulating cycles of HDCT, each supported with PBSC with or progenitor cells and decrease the total number of required without autologous bone marrow. No patients received apheresis procedures. Approaches to PBSC mobilization growth factors post-autologous stem cell transplant, include chemotherapy and/or single or multi-agent GF unless the absolute neutrophils count (ANC) failed to administration; [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] however, the optimal method for PBSC recover to у100/l by day +18 post-transplant. The mobilization is unknown. Investigators have used G-CSF median number of days to recovery of ANC to 100/l, alone, 5,29-32 GM-CSF alone, 33, 34 and combinations with 500/l and 1000/l, and of platelet counts to 20 000/l, interleukin-3 (IL-3) or stem cell factor (SCF) to mobilize 50 000/l and 100 000/l after either cycle 1 or cycle 2 progenitor cells into the circulation. [34] [35] [36] [37] [38] [39] No reported ranof HDCT and the number of febrile days and platelet domized studies exist to evaluate the superiority of one GF and PRBC transfusion requirements was not signifiover another for stem cell mobilization. Small studies cantly different between the two arms of the study. The reported suggest that a sequential combination of IL-3 with duration of hospitalization was similar between study G-CSF may induce a PBSC product which enhances platearms for cycle 1 of HDCT, but was 3.5 days less with let recovery over G-CSF alone. 36, 37 Studies evaluating the arm II compared to arm I (P = 0.0248) for cycle 2 of quality of PBSC products using surrogate markers of stem HDCT. The bone marrow buffy coat and PBSC product cells such as the quantity of CD34 + cells and colonymononuclear cell count (؋ 10 8 /kg) and CD34 ؉ cell count forming unit granulocyte-macrophage (CFU-GM), [38] [39] [40] [41] [42] [43] [44] [45] (؋ 10 6 /kg) collected by each method of stem cell mobilsuggest that G-CSF as a single factor 5, 31, 32, 35 and the combiization was not significantly different. There is questionnation of G-CSF with SCF 42 are superior for stem cell mobable clinical benefit with PBSC products mobilized with ilization than other single GFs without chemotherapy. the combination of G-CSF and GM-CSF vs G-CSF However, there is no clinical evidence to support the use alone. Perhaps different dosages, schedules, or other of these surrogate markers alone to directly compare hematopoietic recovery following HDCT given with PBSC mobilized by different methods. Furthermore, the routine use of GFs post-PBSC transplant has been demonstrated to PBSC collected, hence the concept of sequencing IL-3 with phosphatase Ͻ5 times normal; and (7) the ability to give informed consent. G-CSF or GM-CSF and the combination of SCF with G-CSF. [34] [35] [36] [37] [38] In vitro studies by Bot et al 48 demonstrated synerExclusion criteria included: (1) prior therapy with nitrosurea, thiotepa, melphalan, mitomycin C or carboplatin (if gism between GM-CSF and G-CSF with respect to number, size, and survival of granulocyte progenitors, and support Ͼ6 cycles); (2) Ͼ12 cycles of conventional dose chemotherapy; (3) previous HDCT with autologous stem cell the concept that this GF combination may enhance the number and quality of granulocytic progenitors mobilized transplant; (4) absolute requirement for GF in conjunction with conventional chemotherapy; or (5) pelvic irradiation. for subsequent pheresis collection. 48 We therefore performed a phase III study and reported on the mobilization All pre-transplant therapy, including hormone therapy, must have been completed at least 4 weeks before study of PBSC with G-CSF (10 g/kg/day) and GM-CSF (5 g/kg/day) given for 6 days before and during a median entry. Additional exclusion criteria included congestive heart failure, cardiac arrhythmias requiring treatment, HIV of 4 days of apheresis collections. 47 After HDCT and stem cell transplantation, patients were randomly assigned to infection, viral hepatitis, other active infections, bleeding disorders, pregnancy and lactation. Fertile men and women receive or to not receive G-CSF and GM-CSF. The median days to recovery to an ANC of 100/l (9 vs 11.5, agree to use effective contraception. P = 0.0005) and of 500/l (10 vs 16, P = 0.0004) was significantly less in those patients receiving GFs post-transPatient characteristics plant. However, because the early phase of neutrophil recovery was so subtly enhanced using GFs post-transplant, Candidates for this protocol had metastatic, recurrent or at high-risk for recurrent malignant disease, and were schedthere was no significant difference in the number of febrile days or infectious episodes. Platelet recovery after cycle 2 uled to receive HDCT (Table 1) . Sixty-three patients were registered, but only 50 are fully evaluable for analysis. of HDCT was slightly compromised with the administration of GF post-transplant. Based on the lack of adverse Thirteen non-evaluable registered patients were removed from the study due to interval development of hepatitis clinical consequences, future studies excluding posttransplant GFs could be initated which would eliminate the (one) or disease progression (three), insurance referral patterns/restrictions (two), subsequent patient refusal to confounding influence of GFs on late neutrophil recovery.
No clinical evidence based on randomized trials is availparticipate (four) or protocol violations (three). Protocol violations included one patient who signed consent forms able supporting the hypothesis that the combination of GM-CSF and G-CSF is superior to either GF alone for PBSC for two competitive protocols and chose the alternative therapy; one patient who had previously received more than mobilization. This study is the first randomized published evaluation comparing two approaches to PBSC mobiliz-12 cycles of chemotherapy; and one patient who was randomized to receive GM-CSF and G-CSF but who ation using GFs alone. We present our findings of the addition of GM-CSF to G-CSF for mobilization of PBSC developed allergy to GM-CSF. products. The study is also unique because of the absence of administration of GFs post-transplant, thus enabling us
Study design more clearly to analyze the effect of the PBSC mobilization approach on neutrophil and platelet recovery after HDCT For PBSC mobilization, patients were randomized to receive either a presumed optimal dose of G-CSF and PBSC transplant. The study question was, given an equal number of phereses products infused, which method (10 g/kg/day) alone (arm I) or the combination of G-CSF (10 g/kg/day) and the probable maximum tolerated dose of mobilization, if any, was superior for hematopoietic recovery.
of GM-CSF in adults (5 g/kg/day) (arm II). GF(s) was/were started 5 days before the first PBSC apheresis and months; (4) WBC у4000/l, ANC у1500/l, platelet nine Ͻ1.5 mg/dl or calculated creatinine clearance Ͼ50 ml/min; (6) bilirubin Ͻ1.5 mg/dl, AST and alkaline were continued throughout apheresis. Beginning on the 6th with a diagnosis associated with high-risk occult bone marrow involvement (prior bone marrow involvement) day after initiation of GF(s), PBSC were collected daily for a total of 4 days using a continuous flow Fenwal CS 3000 received only PBSC support after HDCT. The decision to collect and infuse bone marrow along with PBSC was made (Baxter Health Care Products, Deerfield, IL, USA) bloodcell separator. Procedure parameters included acid citrate prior to collection of PBSC, and without knowledge of each patient's yield of CD34 + cells/kg. After cycle 1 of HDCT, dextrose (ACD) anticoagulant at flow rates calculated to be 1.4 times the patient's blood volume based on height, 12 of 26 patients in arm I and eight of 24 patients in arm II received autologous bone marrow and PBSC support; weight and sex. The ratio of ACD to whole blood was 1:9. Plasma flow rates were calculated from the patient's hemawhereas, after cycle 2 of HDCT, three of eight patients in arm I and five of 11 patients in arm II received both sources tocrit values. The volume of blood processed (6-12 l) was twice the patient's calculated blood volume. Aspiration and of stem cells. Prior to stem cell infusion, patients received diphenhydramine (50 mg) and hydrocortisone (100 mg) cryopreservation of autologous bone marrow occurred on day 3 or 4 of GF(s), with the goal to obtain 2 × 10 8 monointravenously.
Materials and methods
No patients on this protocol were scheduled to receive nuclear cells/kg body weight. Assessment of bone marrow and PBSC products included fresh and post-thaw mono-GF(s) post-autologous bone marrow and/or PBSC transplant. However, if the ANC remained Ͻ100/l on day 18 nuclear cell count (× 10 8 /kg) and CD34 + cell count (× 10 6 /kg), for both arm I and arm II. HDCT on a separate post-stem cell infusion, G-CSF (5 g/kg) was given subcutaneously daily until recovery of ANCϾ500/l. Upon treatment protocol was administered as listed in Table 2 , depending on the diagnosis. Patients received either one recovery to a platelet count of 100 000/l, ANC of 1500/l, and resolution of extramedullary toxicity, a (n = 31) or two (n = 19) cycles of HDCT, each given with autologous stem cell support. Two cycles of therapy were second cycle of HDCT (which may have been different than the first) was given in 19 patients. standard in patients with stage II, III or IV breast carcinoma, recurrent ovarian carcinoma and multiple myeloma. Other diagnoses, predominantly recurrent lymphoma, received a single cycle of therapy. When two cycles of Supportive care HDCT were planned per treatment protocol, only half of the stored bone marrow and PBSC collection were infused Following initiation of HDCT and upon decrease in the ANC to Ͻ500/l, patients received prophylactic antimicroafter each cycle. The product of 2 alternate days of PBSC apheresis was infused for each cycle of HDCT, alternating bials consisting of vancomycin (1 g i.v. daily), ciprofloxacin (750 mg orally every 12 h), fluconazole (400 mg i.v. the products of apheresis days 1 and 3 with 2 and 4 between successive patients. Patients scheduled to receive only one or orally daily), and acyclovir (5 mg/kg i.v. every 8 h). Infection was presumed in patients who developed fever cycle of HDCT were apheresed on only 2 days. In these patients, days 1 and 2 apheresis products were infused with (temperature у38°C) when the ANC was Ͻ1000/l. In patients who developed neutropenic fever, appropriate culthe first cycle.
Patients with bone marrow involvement with tumor or tures and chest X-ray were performed, ciprofloxacin was discontinued, the vancomycin dose was empirically increased to maintain therapeutic drug levels, and ceftazid- Patients with persistent or recurrent fever while neutropenic
despite 7 days of antibiotic therapy were empirically started on amphotericin B (0.5 mg/kg/day). Patients with docu-CVPTC or CVPT 11 7 13 9 mented infections were treated for a total of 10-14 days.
If the fever was of undetermined origin, and subsequently and then every month for 1 year.
Statistical analysis Febrile days, length of stay and transfusion requirements
Clinical endpoints of interest included depth and duration PRBC and platelet transfusion requirements and number of of neutropenia and thrombocytopenia, number of days of days febrile after either cycle 1 and/or cycle 2 of HDCT fever, duration of hospital stay, platelet and PRBC transwere not significantly different for arm I and for arm II fusion requirements, mortality and side-effects from GF (Table 5 ). The duration of hospitalization with cycle 1 of administration. Hematopoietic recovery between arm I and HDCT and when data for cycle 1 and cycle 2 of HDCT arm II was compared by the Log Rank and Breslow statistiwere combined was similar between arms I and II of the cal significance method. The mononculear cell count/kg study. Although patient numbers are small with HDCT and number of CD34 + cells/kg of the PBSC product and cycle 2, the duration of hospitalization was significantly harvested bone marrow, number of febrile days, transfusion shorter in arm II compared to arm I (18 vs 21.5 days, requirements and duration of hospitalization between study P = 0.0248). arms I and II were compared by using the Mann-Whitney Wilcoxon rank sum test.
Mortality of HDCT and toxicity of GF administration The sample size calculations were based on the ability to detect a difference in recovery to an ANC of 100/l and In each arm of the study, two patients expired following 500/l between the two therapies of 3 days (alpha = 0.05;
HDCT due to multi-organ failure and/or disease propower = 0.95; two-sided t-test). Enrollment of 44 patients gression. There was one episode of severe allergic reaction randomly assigned to receive G-CSF with or without GMattributed to GM-CSF; otherwise, there were no significant CSF before and during pheresis was required to detect these side-effects or difference in side-effects between the two differences in recovery to both an ANC of 100/l and arms during mobilization. 500/l. Table 6 shows the total mononuclear cell count × 10 8 /kg and total CD34
Bone marrow and PBSC assessment Results
+ cells × 10 6 /kg for 4 days of harvested Patient characteristics PBSC product for arm I (G-CSF alone, 27 cases), compared to arm II (G-CSF + GM-CSF, 25 cases). A borderline sigOf the 50 patients registered and evaluable, 26 were rannificant difference (P = 0.0511) in the number of monodomized to receive G-CSF alone (arm I) and 24 were rannuclear cells collected in the apheresis products was seen domized to receive G-CSF and GM-CSF (arm II) for PBSC favoring arm I (G-CSF alone). No differences were demonmobilization. Patient characteristics and HDCT regimens strated either in the number of mononuclear cells or CD34 + are listed in Tables 1 and 2 , respectively. Breast cancer and cells collected from bone marrow between the two arms of lymphoma were the most frequent diagnoses in this patient the study (Table 6 ). population. Patients were randomly assigned to study arm Tables 7 and 8 compare the number of mononuclear I or II without relationship to diagnosis, HDCT regimen, cells × 10 8 /kg and CD34 + cells × 10 6 /kg infused from bone sex or age. The distribution of patient characteristics and marrow and PBSC between the two study arms with each HDCT regimens appear balanced between the two arms of cycle of HDCT. Only in cycle 2 of HDCT were any differthe study. Apheresis for PBSC was performed and analyzed ences in these values noted. The CD34 + × 10 6 /kg cell count on 52 patients, although only 50 of these patients received infused in PBSCs on arm I was a median of 3.78 (range treatment. Post-thaw cell counts were available for 46 of 1.44-18.80), compared to 18.135 (range 3.66-48.15) in arm these patients.
II (P = 0.0453) ( Table 8 ). This may be due to relatively small numbers of patients receiving a second transplant, Hematopoietic recovery and/or patient selection.
After cycle 1 of HDCT, neutrophil recovery to 100/l, 500/l and 1000/l was not significantly different between Discussion arm I (G-CSF) and arm II (G-CSF and GM-CSF) of the study (Table 3) . Platelet recovery to 20 × 10 3 /l, 50 × 10 3 /l and 100 × 10 3 /l was also not statistically difAt present, the number of CD34 + cells in stem cell collections is considered the best predictor for the speed of neuferent between the two study arms (Table 3) . At the time of analysis only 19 patients received a second cycle of trophil and platelet engraftment after HDCT. When the infused number of CD34 + cells/kg exceeds 2.5 × 10 6 in HDCT, eight on arm I and 11 on arm II. Hematopoietic recovery was also similar between arms I and II when data patients mobilized with chemotherapy and GFs, nearly all patients have prompt recovery of neutrophils and platelets, were combined for cycles 1 and 2 of HDCT; however, the median day to recovery of ANC to 500/l and to 1000/l but there appears to be an obligate period of 8-10 days required for the CD34 + cells to differentiate into mature was 2 and 4 days, respectively, less in arm II compared to arm I. These differences were not significant (Table 4 ). In cells. 41, 42, 45, 49 If less than this number of CD34 + cells is infused, hematopoietic recovery is more heterogenous and cycle 1, five patients (two in arm I and three in arm II) required G-CSF on day 18 for failure to recover neutrophils less predictable. Currently, chemotherapy followed by GFs results in the greatest mobilization of progenitor and CD34
+ of 100/l, by day 18. No patient required G-CSF in cycle 2.
925 Table 3 Hematopoietic recovery after HDCT cycle 1 Breslow. 48 suggested that the addition of GM-CSF to G-CSF may improve the yield of PBSC proGFs alone.
Recovery time (days) after HDCT cycle 1 G-CSF (arm I) G/GM-CSF

G-CSF ؉ GM-CSF vs G-CSF for mobilization of PBSC
An alternative to the use of chemotherapy plus GFs for ducts. To detect this difference more readily, patients did not receive GFs post-transplant, except in cases in which mobilization of stem cells is the use of single GFs alone or combinations of GFs. The use of GFs alone or in combithe ANC did not recover to 100/l by day 18. Patients also received an identical number of apheresis products, not a nation for PBSC mobilization allows for scheduled apheresis, avoidance of hospitalization and/or neutropenic comtargeted CD34 + cell number. The absence of post-transplant growth factors allows the contribution of PBSC to early plications associated with chemotherapy, and does not result in significant long-term toxicity. The optimal GF(s), neutrophil recovery to be evaluated, not masked by any residual endogenous marrow stem/progenitor cell contridose, and schedule for stem cell mobilization is unknown. It is deduced from indirect evidence, sequential studies (nonbution to early recovery. Analyzing a total of 69 courses of HDCT, we detected a modest, but non-significant randomized) and the numbers of CFU-GM or CD34
+ cells mobilized, that G-CSF is superior to GM-CSF for mobilizenhancement of neutrophil recovery by the addition of GM-CSF to G-CSF for PBSC mobilization. There were no sigation of stem cells into the peripheral blood. Peters et al 10 illustrated in sequential groups of patients treated with nificant differences between the two study arms in number of days with fever and duration of hospital stay, nor in HDCT followed by autologous bone marrow plus G-CSF or GM-CSF mobilized PBSC, that the number of apheresed transfusion requirements. However, the results of our study should not discourage future trials of cytokine combi-CFU-GM and CD34
+ cells were greater, hematopoietic recovery shorter, and transfusions and complications less nations for PBSC mobilization, as small yet significant differences in outcomes may be observed in studies with in G-CSF-mobilized patients. Analysis of single arm studies in which G-CSF or GM-CSF-mobilized PBSC were greater patient numbers. This study could be criticized because of the addition of used without bone marrow also suggest an advantage for G-CSF.
5, [31] [32] [33] Although taken as a whole, it is suggested marrow in patients without a significant probability of marrow involvement, and the heterogenous diagnosis and conthat G-CSF is more effective than GM-CSF as a PBSC mobilizing agent, neither agent is consistently effective in ditioning regimen. However, the addition of autologous marrow without post-transplant growth factor is very patients who have been heavily pre-treated. These studies are confounded by comparison of patients with different unlikely to enhance early hematopoietic recovery and thus mask an enhanced recovery with infusion of PBSC proamounts and types of prior therapy, and the variable use of GFs post-PBSC transplant. Nevertheless, several groups ducts mobilized with GM-CSF in addition to G-CSF. Importantly, although the patient diagnoses were variable, have now reported rapid and predictable hematopoietic recovery using G-CSF-mobilized PBSC in patients without this trial excluded all patients who had been extensively pre-treated. Extensive prior therapy, defined by the number extensive chemotherapy history prior to mobilization. 5, [29] [30] [31] It is also unclear if hematopoietic recovery is more rapid of chemotherapy cycles or exposure to 'stem cell poisons' (such as nitrosoureas) and radiation treatment to marrowusing PBSCs collected after chemotherapy given with or without GF. Regardless of the method of PBSC mobilizrich areas of bone, is the primary determinant of the number of stem cells mobilized by any single strategy. 50,51 Furtheration, failure to mobilize an adequate number of stem cells is associated with type and number of cycles of previous more, although the number of HDCT regimens were broad, all the regimens used are known to be intensely and simichemotherapy and prior radiation treatment.
50,51
Because of a bias in favor of G-CSF as the optimal mobilarly myelosuppressive, and the interval between initiation of the HDCT regimen and infusion of stem cells was similizing agent, the ease in scheduling apheresis and less toxicity using GF alone, and the uncertainties of the optimal lar. It is possible that a favorable effect could be seen in a more homogenous group of patients with minimally or approach to mobilization (chemotherapy vs GFs), we asked in this study if there was any detectable additive or synerextensively treated disease. Our results resemble other unpublished ongoing studies gistic effect resulting from the addition of GM-CSF to G-CSF in mobilizing progenitor or stem cells prior to HDCT.
where the addition of IL-3 to GM-CSF or the addition of
